Table 2. Comparison of bISH for albumin, Hep Par1 and Arginase for the diagnosis of hepatocellular carcinoma.
ALBUMIN + | HEP PAR1+ | ARGINASE+ | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N=93 | N=89 | N=87 | |||||||||||||
%+ | Score0 | Score1 | Score2 | Score3 | %+ | Score0 | Score1 | Score2 | Score3 | %+ | Score0 | Score1 | Score2 | Score3 | |
All cases | 99% | 1 | 0 | 3 | 89 | 84% | 14 | 7 | 8 | 60 | 83% | 15 | 11 | 18 | 43 |
Grade 1 | 100% | 0 | 0 | 0 | 6 | 100% | 0 | 0 | 0 | 4 | 100% | 0 | 1 | 2 | 1 |
Grade 2 | 100% | 0 | 0 | 1 | 50 | 98% | 1 | 5 | 4 | 39 | 90% | 5 | 5 | 11 | 27 |
Grade 3 | 99% | 1 | 0 | 2 | 33 | 64% | 13 | 2 | 4 | 17 | 71% | 10 | 5 | 5 | 15 |
Score 1=< 5% of tumor staining positive
Score 2=5% to 50% of tumor staining positive
Score 3> 50% of tumor staining positive
Albumin was evaluated using in situ hybridization
Hep Par1 and Arginase-1 was evaluated on an immunohistochemistry platform
Grade = grade of differentiation